Dessislava Boneva, MD, joins RetinalGeniX board of directors


Boneva is an experienced surgeon skilled in trauma, surgical critical care, emergency surgery, and acute care surgery.

©rogerphoto -

Image credit: ©rogerphoto -

RetinalGeniX Technologies Inc. announced that Dessislava (Dessy) Boneva, MD has joined the Company’s Board of Directors.

In the press release, RetinalGexiX shared that Boneva is an experienced surgeon skilled in trauma, surgical critical care, emergency surgery, and acute care surgery. She has dedicated her life to saving lives and helping patients recover from traumatic injuries. Today, she has over 10,000 surgeries under her belt, more than 100 publications, over 20 years of experience in her specialty, and remains just as devoted to the profession as she was when she first started.1

Boneva is a faculty member at the University of South Florida (USF) and has received numerous awards throughout her career, among which includes recognition as a Top Doctor and Top Trauma Surgeon and has been published in multiple magazines including Top Doctor's Magazine. Recently, she was featured in the Wall Street Journal and received a Lifetime Achievement Award. 1

She is actively involved in educating students, residents, and critical care fellows as part of the Graduate Medical Education (GME) programs at her hospital. She is also a Fellow of the American College of Surgeons.1

In the press release1, Boneva is quoted on her appointment to the board, saying “I am very excited about joining the RetinalGeniX Board of Directors. I believe the Company’s numerous patents and technologies are likely to help patients soon, both as preventive measures and therapeutically. I am convinced that RetinalGeniX's pharmaco-genetic technology has tremendous potential to prevent blindness, reveal early signs of systemic diseases and reduce healthcare costs. The Board and Clinical Advisers of RetinalGeniX are some of the world's leading ophthalmologists, I am honored to be a part of the team.”

Jerry Katzman, MD, Chairman, President, and CEO of RetinalGeniX Technologies Inc., shared his excitement for the newest board member, saying, “We are delighted to welcome Dessy aboard. She is truly inspiring with her medical and surgical knowledge, expertise, personal and professional accomplishments, and passionate dedication to her patients and students.”1

RetinalGeniX is currently developing technologies and software such as DNA/RNA/GPS™ Pharmaco-Genetic Mapping™ software to predict and associate early diagnosis of systemic disease in conjunction with high-resolution retinal imaging. The company is developing a high-resolution 24/7 real-time home and remote monitoring system to assist both physicians and patients. The use of the system does not require dilation of the pupil.1

In the area of ophthalmology, the Company has started conducting pharmaceutical clinical studies for treating dry Age-Related Macular Degeneration (AMD) and Alzheimer's/Dementia complex as part of its DNA/RNA/GPS™ initiative. RetinalGeniX has also filed two provisional patents related to these studies and formed an institutional review board to launch a 390-patient clinical study that is intended to validate the relative suitability of anti-VEGF ocular injection treatments for patient candidates with wet AMD.1

RetinalGeniX Technologies Inc. Appoints Dessy Boneva, MD, FACS to the Board of Directors. RetinalGeniX Technologies Inc. December 4, 2023. Accessed December 12, 2023.

Related Videos
Video 4 - "Treating Geographic Atrophy in Patients with Concurrent Neovascular AMD"
Video 3 - "Managing a Patient with Bilateral Geographic Atrophy"
Video 2 - "FDA-approved Therapies for Geographic Atrophy"
Video 1 - "Geographic Atrophy: Overview, Diagnosis, and Progression"
Marion Munk, MD, PhD, presenting slides
Marion Munk, MD, PhD, presenting slides
Retinal Inner Layer Disorganization and OCT in Uveitic Macular Edema: Insights from Dr. Amitha Domalpally
ARVO 2024: Study Reveals Faricimab's Potential for Extended Dosing in nAMD
© 2024 MJH Life Sciences

All rights reserved.